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Abstract 
Background: Understanding the underlying mechanism of thrombus formation and its components is critical for 
effective prevention and treatment of ischemic stroke. The generation of thrombotic clots requires conversion of solu-
ble fibrinogen to an insoluble fibrin network. Quantitative features of intracranial clots causing acute ischemic stroke 
can be studied on non-contrast enhanced CT (NECT). Here, we evaluated on-admission fibrinogen and clot burden in 
relation to stroke severity, final infarct volume and in-hospital mortality.
Methods: We included 132 consecutive patients with ischemic stroke and presence of hyperdense artery sign admit-
ted within 6 h from symptom onset. Radiological parameters including clot area (corresponding to clot burden) and 
final infarct volume were manually determined on NECT. National Institute of Health Stroke Scale (NIHSS) was used to 
quantify disease severity and short-term outcome.
Results: Median patient age was 77, 58 % were women, and 63 % had an occlusion of the proximal middle cerebral 
artery segment. Thrombolysis was performed in 60 % and thrombectomy in 44 %. We identified several independent 
associations. Higher fibrinogen levels on admission were associated with smaller clot burden (p = 0.033) and lower 
NIHSS on admission (p = 0.022). Patients with lower fibrinogen had a higher clot burden (p = 0.028) and greater final 
infarct volume (p = 0.003). Higher fibrinogen was associated with a lower risk of in-hospital death or NIHSS score >15 
if discharged alive (p = 0.028).
Conclusions: Our study suggests that intracranial clot burden in acute ischemic stroke is associated with fibrinogen 
consumption, and shows a complex relationship with disease severity, infarct size and in-hospital survival.
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Background
Cerebral blood flow can be interrupted by occlusion of 
major intracranial arteries and result in acute ischemic 
stroke [1]. Fibrinogen is a glycoprotein that helps in the 
formation of occluding blood clots. Fibrin, the product 
of thrombin’s proteolytic cleavage of fibrinogen, provides 
its biophysical and biochemical support [2]. Arterial 
thrombi are essentially composed of platelets with fibrin, 
whereas venous thrombi are rich of red-blood cells [3, 4]. 
Tissue-plasminogen activator (t-PA) is an thrombolytic 
agent for the treatment of acute ischemic stroke which 
dissolves fibrin bonds in the clot by activating plasmi-
nogen and is approved for iv treatment up to 4.5 h from 
symptom onset [5].
Several large prospective studied identified high 
fibrinogen plasma levels as an independent predictor of 
myocardial infarction and ischemic stroke [6–8]. While 
elevated fibrinogen is associated with other cardiovas-
cular risk factors including age, smoking, blood pressure, 
and cholesterol, the relationship with stroke persisted 
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recently, Potpara and coworkers identified the associa-
tion of plasma fibrinogen with poor functional 30-day 
outcome in ischemic stroke [10]. Liu and coworkers stud-
ied fibrinogen levels in different stroke etiologies strati-
fied according to the Trial of Org 10,172 in Acute Stroke 
Treatment (TOAST) classification [11]. While fibrinogen 
levels did not differ among the stroke subtypes, elevated 
d-dimer levels, a specific fibrinolysis marker, were typical 
for cardioembolic etiology.
Response to t-PA therapy and also efficacy of 
thrombectomy varies and presumably depends on a wide 
range of variables including location, time frame and 
radiological characteristics such as width, length and 
structure [12]. To this end, qualitative clot characteristics 
can be assessed on non-contrast enhanced CT (NECT). 
Fibrin is loosely packed in thrombi of cardioembolic ori-
gin and has better chances of recanalization using t-PA 
[4, 13]. Thrombi derived from large artery arterioscle-
rosis (LAA) comprise densely packed fibrin and are less 
likely to be resolved by medical strategies aimed at dis-
solving fibrin bonds.
An acute lowering of fibrinogen can be caused by deg-
radation due to hyperreactive or stimulated systemic 
coagulation, resulting in increased thrombin formation 
and platelet activation [14]. Such rapid alterations of 
fibrinogen levels in the peripheral circulation are asso-
ciated with clot burden in various acute thrombotic 
conditions. Fibrinogen consumption and a relationship 
with thrombin production has been reported for acute 
myocardial infarction, whereas this was not the case 
for stable coronary artery disease [15]. Notably, fibrino-
gen consumption is associated with a larger clot burden 
in pulmonary embolism [16]. Thus, it seems likely that 
fibrinogen degradation takes place in acute ischemic 
stroke caused by thrombotic occlusion of intracranial 
arteries. Here, we aimed to investigate the relationship 
between on-admission fibrinogen levels and radiological 
clot burden quantified within the first 6 h from symptom 
onset in acute ischemic stroke in relation with early clini-
cal and radiological markers of outcome.
Methods
Study design
We reviewed medical records of consecutive patients 
admitted to the Christian Doppler Medical Center with 
acute ischemic stroke. The study period was January 2013 
to January 2015. During the entire study period, there 
was no change of leading stroke staff, all three senior 
physicians were full-time neurologists.
The inclusion criteria were as follows: (a) age ≥18 years; 
(b) diagnosis of ischemic stroke; (c) proven intracranial 
vessel occlusion with quantifiable clot dimensions within 
6 h after stroke onset (Fig. 1a); (d) presence of a hyper-
dense artery which was defined as “spontaneous visibility 
of complete or a part of” intracranial artery in segments 
with no calcifications [17]. We excluded cases without 
a hyperdense artery sign or non-ischemic intracerebral 
pathology was detected. For the purpose of group com-
parison we compiled a “non-MCA” group, which con-
cerned all intracranial vessels other than branches of the 
middle cerebral artery.
Ethics section
The protocol was in accordance with the ethical stand-
ards of our hospital’s committee for the protection of 
human subjects (protocol UN 2553). According to Aus-
trian regulations, individualized informed consent is not 
Fig. 1 Study design. a Screening and inclusion of patients in the pre-
sent analysis. b Diagram of the planned successive hypotheses about 
relationship between on-admission fibrinogen and imaging and 
clinical findings. Full arrows indicate direct associations and dotted 
arrows indicate the assumed indirect (mediated “through” mediator 
variables) associations. CTA angiography by computed tomography, 
DSA digital subtraction angiography, MRA angiography by magnetic 
resonance, NECT non-enhanced computed tomography, NIHSS 
National Institutes of Health Stroke Scale, rt-PA recombinant tissue 
plasminogen activator
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required for routinely collected clinical and radiologic 
data as used in this study.
Institutional standard procedure with acute stroke patients
Patients were treated according to the national stroke 
guidelines and local standard operation procedures for 
neuroimaging and mechanical thrombectomy. Mini-
mal diagnostic work-up procedures included labora-
tory examinations on admission, extracranial Doppler 
und Duplex sonography of the brain-supplying arteries, 
monitoring at the stroke unit, extracranial transthoracic 
echocardiography, 24-h ECG monitoring and follow-up 
CT within 7  days. In-hospital variables were collected 
retrospectively for all patients via medical chart review 
and the IMPAX system (AGFA Healthcare, Mortsel, Bel-
gium). Clinical disability on admission and transfer were 
routinely recorded with the National Institutes of Health 
Stroke Scale (NIHSS) by certified physicians.
Quantification of the clot burden
NECT and CT angiography scans were performed in a 
multidetector CT scanner Sensation 64 (Siemens, Erlan-
gen, Germany). The NECT scans were reconstructed into 
4 mm thick adjacent slices through the entire brain. Two 
experienced neurologists blinded to the clinical infor-
mation independently reviewed rated the scans. In case 
of disagreement, they discussed until a consensus was 
reached. The clot area was measured by delineating the 
hyperdense artery on NECT that corresponded to occlu-
sion site on CT-A/MR-A/conventional angiography and/
or matched with final infarct area. The region of interest 
was drawn around the hyperdense part of the artery and 
the area was automatically calculated using IMPAX soft-
ware. When hyperdense artery area was seen on more 
than one slice the measured areas were summed [12]. In 
this regard, we used “clot area” (in mm2) as a measure of 
clot burden.
Quantification of the final infarct volume
The follow-up CT scans were examined for infarct 
demarcation. The infarct area was manually delineated 
on each CT slice (4  mm height) which yielded area in 
cm2. Finally, the volume in cm3 was summed from the 
measured area and the corresponding slice thickness 
[18].
Data analysis
Data analysis was conceived as a set of regressions 
aimed to test consecutive hypotheses about associations 
(“effects” used in the meaning of regression analysis, not 
necessarily implying causal relationship) between on-
admission fibrinogen levels and co-incident or subse-
quent imaging and clinical findings (Fig. 1b). The analysis 
was driven by temporal and pathophysiological ration-
ales: (a) the first step tested the association between on-
admission fibrinogen and clot area (representing clot 
burden); (b) the next step tested the association between 
on-admission fibrinogen and clot area (simultaneously 
and separately) with NIHSS score at presentation. Dif-
ferences in the strength of simultaneous and separate 
independent associations were to be considered an 
indication of possible direct and mediated (through the 
“effect” on clot area) “effects” of on-admission fibrinogen. 
In the same way, (c) the third step tested the association 
between on-admission fibrinogen and/or clot area and 
the final infarct volume; (d) the final step, following this 
concept, tested the association between on-admission 
fibrinogen and in-hospital clinical outcomes, account-
ing (simultaneously or separately) for clot area, final 
infarct volume and disease severity at presentation. For 
this purpose, a composite outcome of in-hospital death 
or survival but with NIHSS score >15 at discharge (mod-
erate/severe or severe stroke) was analyzed. Continu-
ous outcomes (clot area, infarct volume, NIHSS scores) 
were analyzed by fitting general linear models, whereas 
the composite of in-hospital mortality/NIHSS score at 
discharge >15 was analyzed by fitting modified Poisson 
regressions with robust error variance [19] to yield rela-
tive risks. Where required for achievement of normality 
of residuals, dependent and/or independent continuous 
variables were ln-transformed. All analyses were per-
formed in SAS 9.3 for Windows (SAS Inc., Cary, NC).
Results
Patient characteristics and their relationship 
to on‑admission fibrinogen levels
A total of 132 patients fulfilled the inclusion criteria. 
Most hyperdense artery signs could be confirmed by the 
performance of a CT-A (84.1  %) (Fig.  1a). Demograph-
ics and further characteristics of the cohort are shown in 
Table 1.
On-admission fibrinogen ranged between 3.1 and 
24.3  μmol/L and higher values were independently 
associated with older age (p = 0.002), higher C-reactive 
protein (p  <  0.001), history of diabetes (p =  0.038) and 
history of heart failure (p = 0.020) (see Additional file 1: 
Table S1).
Relationship between on‑admission fibrinogen levels 
and clot area (clot burden)
Clot area ranged from 2.5 to 211  mm2 (Table  1). With 
adjustment for sex, history of carotid stenosis >50  % 
and type of the affected vessel (the only covariates with 
multivariate p  <  0.1), higher on-admission fibrinogen 
was independently associated with a lower clot area 
(Table 2).
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Relationship between on‑admission fibrinogen levels, 
clot area (clot burden) and severity of symptoms 
at presentation
NIHSS scores at presentation ranged from 0 to 32 points 
(Table 1). With adjustment for time elapsed since symptom 
onset to imaging, age, C-reactive protein and serum glu-
cose levels, type of the affected vessel and clot area (the only 
covariates with multivariate p  <  0.1) higher on-admission 
fibrinogen was independently associated with lower NIHSS 
scores (Table 3, Model 1). Higher clot area was associated 
with higher NIHSS scores but with borderline statistical 
Table 1 Patient characteristics (N = 132)
Characteristic Values
Demographics
 Age (years) 77 (19–97)
 Men 55 (41.7)
Medical history
 Prior stroke/TIA 17 (12.9)
 Atrial fibrillation 67 (50.8)
 Peripheral artery disease 11 (8.3)
 Carotid stenosis >50 % 15 (11.4)
 Arterial hypertension 93 (70.5)
 Diabetes mellitus 21 (15.9)
 Chronic heart failure 18 (13.6)
 Use of antiplatelets 41 (31.1)
 Use of anticoagulants 12 (9.1)
 Use of any antithrombotic 53 (40.2)
Stroke type by TOAST
 Cardioembolic 77 (58.3)
 Unknown 37 (28.0)
 Large artery atherosclerosis 15 (11.4)
 Other 3 (2.3)
Clinical presentation
 NIHSS (points) 16 (0–32)
 Serum glucose (mmol/L) 6.7 (3.1–12.9)
 HbA1c (mmol/L) 5.5 (4.3-8.5)
 Fibrinogen (μmol/L) 10.5 (3.1–24.3)
 C-reactive protein (mg/L) 0.45 (0.01–21.2)
Acute treatment
 Thrombolysis (rt-PA) 79 (59.9)
 Thrombectomy 58 (43.9)
Thrombectomy outcome (TICI)
 No perfusion (0) 10/58 (17.2)
 Penetration, no distal filling (1) 3/58 (5.2)
 Perfusion, <50 % distal filling (2a) 3/58 (5.2)
 Inadequate (0–2a total) 16/58 (27.6)
 Perfusion, >50 % distal filling (2b) 15/58 (25.9)
 Full perfusion (3) 27/58 (46.5)
 Adequate (2b–3 total) 42/58 (72.4)
Imaging particulars
 Symptoms to image (min) 116 (17–350)
 Affected vessel
  Middle cerebral artery proximal 83 (62.9)
  Middle cerebral artery distal 30 (26.6)
  Basilar artery 8 (6.1)
  Vertebral artery 6 (4.6)
  Posterior cerebral artery 3 (2.3)
  Anterior cerebral artery 1 (0.8)
  Other vessel 1 (0.8)
 Clot area (mm2) 25.2 (2.5–211)
 Final infarct volume (mm3) 37.3 (0–518)
 Control image finding
Table 1 continued
Characteristic Values
  Infarction 88 (66.7)
  Hemorrhagic infarction 20 (15.2)
  Resolution (infarct volume = 0) 11 (8.3)
  None 13 (9.9)
Clinical outcome
 In-hospital mortality 26 (19.7)
 NIHSS at discharge (points) 6 (0–30)
Data are median (range) or absolute numbers (percentage)
HbA1c glycated hemoglobin, NIHSS National Institutes of Health Stroke Scale, 
rt-PA recombinant human tissue plasminogen activator, TIA transitory ischemic 
attack, TICI thrombolysis in cerebral infarction grading, TOAST Trial of Org 10172 
in Acute Stroke Treatment
Table 2 Independent association between  on-admission 
fibrinogen and  clot burden represented by  the clot area: 
summary of multivariate analysis
Ln-transformed clot area values were analyzed and results are presented as 
geometric means ratio (GMR) with 95 % confidence intervals by unit or level 
change in an independent analysis
The initial general linear model fitted to ln(clot area) included all independents 
selected from the variables depicted in Table 1 (except for symptom severity 
on-admission [NIHSS], acute treatment, final infarct volume, control image 
finding and clinical outcome) based on a trend towards univariate association 
with this outcome (p < 0.1) [ln(fibrinogen), sex, history of carotid stenosis, 
affected blood vessel (proximal or distal middle cerebral artery, or “non-middle 
cerebral artery”), age and prior use of antiplatelets]. Variables from this full 
model were then successively removed (age p = 0.562, prior antiplatelet 
use p = 0.115) in the order of the highest p value, if p > 0.100 (backward 
elimination). Two-term interactions between ln(fibrinogen) and each of the 
other effects remaining in the model were tested, but were insignificant with 
p > 0.500 and excluded. The final model is shown
a Since on-admission fibrinogen was ln-transformed (to achieve normality of 
residuals), the “effect” of on-admission fibrinogen is presented as GMR by 2.718-
fold increase
Independents GMR (95 % CI) p value
On-admission fibrinogen (by 2.718-fold)a 0.639 (0.424–0.964) 0.033
Men (vs. women) 1.453 (1.105–1.911) 0.008
History of carotid stenosis >50 % 1.485 (0.972–2.269) 0.068
Proximal vs. distal middle cerebral artery 
(MCA)
2.445 (1.770–3.376) <0.001
Proximal MCA vs. “non-MCA” artery 1.535 (1.039–2.268) 0.038
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significance when fibrinogen was in the model (p = 0.054; 
Table  3, Model 1). In separate models (with all other 
effects) including either fibrinogen (Table  3, Model 2) or 
clot area (Table 3, Model 3), each were independently asso-
ciated with more severe symptoms at presentation. Follow-
ing independent associations were evaluated: on-admission 
fibrinogen—clot area; on-admission fibrinogen—symptom 
severity at presentation; clot area—symptom severity at 
presentation, attenuation of “effects” of fibrinogen and clot 
area on symptom severity when both were accounted for 
the assumption that the “effect” of on-admission fibrinogen 
on symptom severity is at least in part mediated through its 
“effect” on the clot area (Fig. 2). 
Relationship between on‑admission fibrinogen, clot 
burden and final infarct volume
The relationship between on-admission fibrinogen, clot 
area and final infarct volume appeared complex and con-
ditional on the affected vessel (Fig.  1 depicts individual 
values by type of the affected vessel). With adjustment 
for C-reactive protein and glucose levels, performed 
thrombectomy [options: not done, done but inadequate 
perfusion (TICI grade 0–2a) or adequate (TICI grade 
2b–3)] and type of the affected vessel (the only covariates 
with multivariate p < 0.1), higher on-admission fibrinogen 
was independently associated with a lower infarct volume 
(Table 4). In contrast, larger clot area was associated with 
a higher infarct volume, but only in the case of proximal 
MCA (p = 0.069 for the clot area*vessel type interaction) 
(Table  4) [Fig.  2 depicts adjusted regressions of ln(infarct 
volume) on ln(clot area) by vessel type]. The association 
between on-admission fibrinogen and infarct volume was 
unchanged when the clot area was removed, and the asso-
ciation between clot area and infarct volume remained 
unchanged when fibrinogen was removed from the model 
(not shown).
Relationship between on‑admission fibrinogen, clot 
burden, symptom severity at presentation, final infarct 
volume and clinical outcomes—in‑hospital mortality 
and symptom severity in hospital survivors
A total of 26 patients (19.7  %) died during the hospital 
stay (Table  1). NIHSS score at discharge in survivors 
(n = 106) varied between 0 and 30 (Table 1) and was >15 
(moderate/severe or severe stroke) in 27 (25.5 %) of them. 
Overall, 53 (40.2  %) patients either died in hospital or 
were discharged with NIHSS score >15.
We found that higher on-admission fibrinogen was 
associated with a lower risk of in-hospital death/NIHSS 
score at discharge >15 (Table 5, Model 1). This was con-
firmed after adjustment for age, sex, time since symptom 
onset to imaging, C-reactive protein and glucose levels 
Table 3 Independent association of on-admission fibrinogen and clot burden represented by the clot area with severity 
of symptoms at presentation (NIHSS): summary of multivariate analysis
Ln-transformed NIHSS scores were analyzed and results are presented as geometric means ratio (GMR) with 95 % confidence intervals by unit or level change in an 
independent
All variables depicted in Table 1 (except for acute treatment, control image finding, final infarct volume and clinical outcome) were tested for at least a trend (p < 0.1) 
of univariate association with the NIHSS score at presentation. Ln(fibrinogen), clot area, time since symptom onset to imaging (surrogate for admission), age, 
C-reactive protein, type of the vessel affected, serum glucose and history of heart failure met this criterion, but the last variable was removed from the final model due 
to p > 0.5. Three models were fitted differing regarding inclusion of both ln(fibrinogen) and clot area (Model 1), or just ln(fibrinogen) (Model 2) or just clot area (Model 
3) along with other effects. The interaction terms between ln(fibrinogen) or clot areal and vessel type were highly insignificant
NIHSS National Institutes of Health Stroke Severity scale
a Since on-admission fibrinogen was ln-transformed (to achieve normality of residuals), the “effect” of on-admission fibrinogen is presented as GMR by 2.718-fold 
increase
Independents GMR (95 % CI) p value
Model 1
 On-admission fibrinogen (by 2.718-fold)a 0.683 (0.473–0.987) 0.042
 Clot area (by 10 mm2) 1.039 (0.999–1.081) 0.054
 Symptom onset to image (by 10 min) 0.984 (0.972–0.997) 0.023
 Age (by 5 years) 1.507 (1.010–1.093) 0.014
 C-reactive protein (by 1 mg/L) 1.092 (1.045–1.142) <0.001
 Serum glucose (by 1 mmol/L) 1.064 (1.007–1.124) 0.027
 Proximal vs. distal middle cerebral artery (MCA) 1.454 (1.110–1.904) 0.007
 Proximal MCA vs. “non-MCA” artery 1.866 (1.355–2.570) <0.001
Model 2 (clot area not included; shows just fibrinogen—all other effects similar as in Model 1)
 On-admission fibrinogen (by 2.718-fold)a 0.649 (0.449–0.938) 0.022
Model 3 (fibrinogen not included; shows just clot area—all other effects similar as in Model 1)
 Clot area (by 10 mm2) 1.045 (1.005–1.087) 0.028
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and type of the affected vessel (covariates found indepen-
dently associated with on-admission fibrinogen or clot 
area or final infarct volume or NIHSS score at presenta-
tion, Tables 1, 2, 3, 4), and thrombectomy.
With the same adjustments, higher clot area (Table 5, 
Model 2), larger infarct volume (Table  5, Model 3) and 
higher NIHSS at presentation (Table  5, Model 4) were 
each associated with a higher risk of in-hospital death/
NIHSS score at discharge >15.
In a full model (Table 5, Model 5), i.e., with all “default 
adjustments” and including fibrinogen, clot area, infarct 
volume and NIHSS at presentation—only higher NIHSS 
at presentation (p < 0.001) remained independently asso-
ciated with an increased risk.
The sequence of independent associations between 
on-admission fibrinogen and clot area, fibrinogen and 
clot area with NIHSS score at presentation, fibrinogen 
and clot area with final infarct volume and associations 
depicted in Table 5. Together with the attenuation of the 
“effects” of on-admission fibrinogen, clot area and infarct 
Fig. 2 Relationship between on-admission fibrinogen, type of the 
affected vessel, clot area (clot burden) and final infarct volume. a On-
admission fibrinogen (μmol/L) (upper panel), clot areas (mm2) (middle 
panel) and final infarct volumes (mm3) according to the type of the 
affected vessel. Dots are individual values, horizontal lines are medians 
(numerical values depicted), boxes indicate upper and lower quartiles 
and bars are inner fences [median ± (1.5 × interquartile range)]. 
Values outside fences are outliers. b Fitted (adjusted) regression of 
ln(infarct volume) on ln(clot area) by vessel type, from the model 
depicted in Table 4 in the main text. MCA middle cerebral artery
Table 4 Independent association of on-admission fibrino-
gen and clot burden represented by the clot area with final 
infarct volume: summary of multivariate analysis
Ln-transformed infarct volume values were analyzed and results are presented 
as geometric means ratio (GMR) with 95 % confidence intervals by unit or level 
change in an independent
All variables depicted in Table 1 [except for severity of clinical symptoms at 
presentation (National Institutes of Health Stroke Scale score), control image 
finding and clinical outcome] were tested for at least a trend (p < 0.1) of 
univariate association with the final infarct volume and were included in the 
model on this criterion. Two-term interactions between on-admission fibrinogen 
and vessel type or treatment with thrombectomy, as well as between clot area 
and thrombectomy were insignificant (p > 0.500) and excluded, whereas clot 
area*vessel type interaction was significant at alpha 0.1 (p = 0.069) and the 
inclusive model had the best fit (Akaike’s information criterion 505.5, Bayesian 
information criterion 508.3) and is depicted
TICI thrombolysis in cerebral infarction grading
a Since on-admission fibrinogen and clot area were ln-transformed (to achieve 
normality of residuals), the “effects” are presented as GMRs by 2.718-fold increase
Independents GMR (95 % CI) p value
On-admission fibrinogen (by 2.718-fold)a 0.221 (0.081–0.601) 0.003
Clot area (by 2.718-fold)a
 If proximal middle cerebral artery (MCA) 
affected
1.712 (1.096–2.676) 0.018
 If distal MCA affected 0.759 (0.354–1.625) 0.475
 If “non-MCA” artery affected 0.612 (0.316–1.707) 0.346
C-reactive protein (by 1 mg/L) 1.275 (1.121–1.451) <0.001
Serum glucose (by 1 mmol/L) 1.173 (1.011–1.362) 0.036
Thrombectomy with TICI 2b–3 vs. no 
thrombectomy
0.377 (0.191–0.743) 0.005
Thrombectomy with TICI 2b–3 vs. TICI 
0–2a
0.513 (0.193–1.363) 0.179
Proximal vs. distal MCA 6.001 (2.501–14.4) <0.001
Proximal MCA vs. “non-MCA” artery 15.4 (6.27–37.7) <0.001
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volume on the clinical outcome when all (together with 
NIHSS at presentation) were in the same model, impli-
cates that the association between on-admission fibrino-
gen and assessed clinical outcomes is mediated through 
its association with clot area, infarct volume and severity 
of disease at presentation.
Discussion
Understanding the underlying mechanism of thrombus 
formation and its consequences is critical for effective 
prevention and treatment of ischemic stroke. This study 
disclosed an independent inverse relation between on-
admission fibrinogen levels and clot burden. This find-
ing points at in vivo fibrinogen consumption in and after 
the process of thrombus formation. Moreover, fibrinogen 
degradation and clot size showed a complex relationship 
with disease severity, infarct size and in-hospital survival.
Fibrinogen is a central molecule in thrombosis and 
hemostasis and implicated in additional conditions 
including as well as in pathologies including inflamma-
tion, host defense, cancer, and neuropathology. Indeed, 
elevated fibrinogen is one of the most prevalent risk fac-
tors for thrombotic disorders [20–22]. We corroborate 
the reported independent associations between higher 
on-admission fibrinogen levels and older age, higher 
C-reactive protein, diabetes and history of cardiovascu-
lar disease in acute ischemic stroke patients. Moreover, 
higher clot burden is associated with more severe stroke 
symptoms at presentation [18, 19]. We expand these 
observations on the basis of our second analysis step by 
reporting an independent association between lower 
fibrinogen and more severe presenting symptoms, and 
between higher clot burden and disease severity. In the 
full model (Table 3) both associations weakened, and the 
Table 5 Association of on-admission fibrinogen, clot burden represented by clot area, final infarct volume and symptom 
severity at presentation (NIHSS score) with the risk of  in-hospital death or survival with NIHSS score at discharge >15: 
summary of multivariate analysis
Data are presented as relative risks (RR) with 95 % confidence intervals
NIHSS National Institutes of Health Stroke Severity scale
TICI thrombolysis in cerebral infarction grading
a Models 1–4 each consisted of a variable of primary interest and a set of default adjustments based on their independent associations with the variables of primary 
interest (Tables 1, 2, 3, 4): age, gender, time elapsed since symptom onset to imaging (reflects admission), C-reactive protein and glucose levels on admission, affected 
vessel (proximal or distal middle cerebral artery or “non-MCA” artery) and performed thrombectomy (none, with perfusion TICI grade 0–2a or grade 2b–3). Model 5 
included all variables of primary interest and all adjustments
b Since on-admission fibrinogen was ln-transformed (as in all previous models), the “effects” are presented as GMRs by 2.718-fold increase
Independents RR (95 % CI) p value
Models 1–4: variable of interest + default adjustmentsa
 Model 1—variable of interest: on-admission fibrinogen
  On-admission fibrinogen (by 2.718 fold)b 0.478 (0.247–0.924) 0.028
 Model 2—variable of interest: clot area
  Clot area (by 10 mm2) 1.057 (1.013–1.104) 0.010
 Model 3—variable of interest: final infarct volume
  Final infarct volume (by 10 mm3) 1.030 (1.019–1.043) <0.001
 Model 4—variable of interest: NIHSS at presentation
  NIHSS at presentation (by 1 score point) 1.097 (1.071–1.123) <0.001
 Model 5—full model: all variables of interest + adjustments
  On-admission fibrinogen (by 2.718-fold)b 0.790 (0.445–1.401) 0.420
  Clot area (by 10 mm2) 0.990 (0.942–1.031) 0.559
  Final infarct volume (by 10 mm3) 1.015 (0.998–1.032) 0.084
  NIHSS at presentation (by 1 score point) 1.087 (1.060–1.114) <0.001
  Age (by 5 years) 1.065 (0.965–1.176) 0.208
  Male gender 1.205 (0.815–1.784) 0.353
  Symptom onset to imaging (admission) (by 10 min) 0.997 (0.973–1.021) 0.420
  C-reactive protein (by 1 mg/L) 1.032 (0.982–1.084) 0.211
  Glucose (by 1 mmol/L) 1.151 (1.041–1.273) 0.006
  Proximal vs. distal middle cerebral artery (MCA) 0.397 (0.135–1.145) 0.087
  Proximal MCA vs. “non-MCA” artery 2.259 (1.136–4.491) 0.020
  Thrombectomy with TICI 2b–3 vs. no thrombectomy 0.700 (0.404–1.213) 0.204
  Thrombectomy with TICI 2b–3 vs. TICI 0–2a 0.484 (0.268–0.875) 0.016
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latter one reached “only” a borderline statistical signifi-
cance. Since the first-step analysis demonstrated the asso-
ciation between the two, this phenomenon was expected 
and indicated that, at least in part, the “link” between 
on-admission fibrinogen levels and symptoms at presen-
tation “went through” its effect on the clot burden. More-
over, the fact that the strength of association between 
fibrinogen levels and symptom severity was less reduced 
than the strength of association between the clot burden 
and symptom severity suggests that fibrinogen might 
reflect clot perturbations on a finer scale (thrombus for-
mation/lysis) and therefore could be a better indicator of 
the extent of thrombus, while clot burden measurement 
is essentially flawed by imperfect methodology. We pro-
pose that NECT depicts only a part or only the erythro-
cyte-rich part of the thrombus whilst the platelet and/or 
fibrin-rich (and thus hypoattenuating) parts are not vis-
ible on NECT. It also needs to be taken into account that 
intracranial clots are not homogenous and ongoing appo-
sition and endogenous thrombolysis takes place [23, 24]. 
This assumption is backed by findings in ischemic heart 
disease, where proximal and distal of the fibrin-throm-
bocyte rich nidus develop after the local plaque rupture 
in coronary vessels [25]. Local hemodynamics and collat-
erals may also contribute to qualitative and quantitative 
alterations of the clot [23, 26].
The final infarct volume is a consequence of a multi-
tude of factors or their combinations, such as the pres-
ence of collaterals or the choice of treatment, and could 
serve as the stroke outcome surrogate [27]. At the third 
step, the present analysis indicated that both on-admis-
sion fibrinogen (inversely) and clot burden were indepen-
dently associated with the final infarct volume. However, 
the latter association was conditional on the type of the 
affected vessel—it was only relevant in occlusion of the 
middle cerebral artery.
Finally, the most complex relationship observed was the 
relation of on-admission fibrinogen and poor in-hospital 
outcome (death or NIHSS score at discharge >15). This 
points at an independent association between higher fibrin-
ogen and a reduced risk—but not when “intermediate” out-
comes (clot area, final infarct volume, symptom severity at 
presentation) to which fibrinogen was also related, were 
accounted for, suggesting that the “effect” of fibrinogen 
was conveyed “through” these mediators. Although such 
a sequence of events appears mechanistically plausible, 
the present observations should be taken with a caution 
since we considered only the on-admission fibrinogen lev-
els. Fibrinogen levels steadily rise over 120 h after stroke, 
are linked to a poor outcome and are decreases with t-PA 
treatment and subsequently raise risk for intracranial hem-
orrhage [28, 29]. Of note, Sun and coworkers found that the 
decrease in fibrinogen less than 2 g/L multiplies the odds of 
early parenchymal hemorrhage as a complication of intra-
venous thrombolysis by factor 12.8 [30].
The present study has a several limitations, which need 
to be considered in future studies. The retrospective stud-
ies might have introduced bias and we did not assess 
plasma levels of tissue plasminogen activator or plasmin 
activator inhibitor-1 as well as fibrinogen degradation 
products. The major limitation to generalizability, how-
ever, arises from the fact that we studied only patients with 
hyperdense artery signs. Up to 70 % of occlusive thrombi 
on NECT are hyperdense, but there are patients with the 
major vessel occlusion without a hyperdense artery and 
they were not present in our study. Additionally, small 
vessel occlusion i.e. lacunar strokes were not included as 
clot area measurement in non-hyperdense thrombi is 
not plausible. Overall, while we used a timely methodol-
ogy, we admit that smaller hyperdense signs may have 
been missed. On the other hand, the study has several 
strengths—all patients underwent standardized diagnos-
tic and therapeutic procedures, medical history data were 
complete, all radiological assessments were done after pre-
defined criteria by raters blinded to clinical outcomes and 
data were viewed in a sensible and thorough way.
Conclusion
We investigated the relationship between on-admission 
fibrinogen levels and clot burden, symptom severity at 
presentation, and in-hospital clinical and radiological 
outcomes in a moderately sized sample of highly selec-
tive stroke patients with the sign of acute vessel occlusion 
within the first 6  h after the stroke onset. Importantly, 
plasma fibrinogen could predict the majority of clinical 
and radiological outcomes. The results are novel and pro-
vide an important impulse to further unravel dysregula-
tion of coagulation pathways in acute ischemic stroke.
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